|
1
|
Hicke L and Dunn R: Regulation of membrane
protein transport by ubiquitin and ubiquitin-binding proteins. Annu
Rev Cell Dev Biol. 19:141–172. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Love KR, Catic A, Schlieker C and Ploegh
HL: Mechanisms, biology and inhibitors of deubiquitinating enzymes.
Nat Chem Biol. 3:697–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yuan J, Luo K, Zhang L, Cheville JC and
Lou Z: USP10 regulates p53 localization and stability by
deubiquitinating p53. Cell. 140:384–396. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nijman SM, Luna-Vargas MP, Velds A,
Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and
functional inventory of deubiquitinating enzymes. Cell.
123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soncini C, Berdo I and Draetta G: Ras-GAP
SH3 domain binding protein (G3BP) is a modulator of USP10, a novel
human ubiquitin specific protease. Oncogene. 20:3869–3879. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L,
Cai Y, Norberg HV, Zhang T, Furuya T, et al: Beclin1 controls the
levels of p53 by regulating the deubiquitination activity of USP10
and USP13. Cell. 147:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan L, Chen Z, Wang L, Chen C, Li D, Wan
H, Li B and Shi G: Deubiquitination and stabilization of T-bet by
USP10. Biochem Biophys Res Commun. 449:289–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Q, Ou C, Liu M, Xiao W, Wen C and Sun
F: NRAGE promotes cell proliferation by stabilizing PCNA in a
ubiquitin-proteasome pathway in esophageal carcinomas.
Carcinogenesis. 35:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q,
Kong S, Ye J, Gao B and Fang D: USP10 antagonizes c-Myc
transcriptional activation through SIRT6 stabilization to suppress
tumor formation. Cell Rep. 5:1639–1649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niu J, Shi Y, Xue J, Miao R, Huang S, Wang
T, Wu J, Fu M and Wu ZH: USP10 inhibits genotoxic NF-κB activation
by MCPIP1-facilitated deubiquitination of NEMO. EMBO J.
32:3206–3219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS,
Yang GF, Wang P and Fu GH: Prognostic significance of USP10 as a
tumor-associated marker in gastric carcinoma. Tumour Biol.
35:3845–3853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koul R, Rathod S, Dubey A, Bashir B and
Chowdhury A: Comparison of 7th and 8th editions of the UICC/AJCC
TNM staging for non-small cell lung cancer in a non-metastatic
North American cohort undergoing primary radiation treatment. Lung
Cancer. 123:116–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang M, Hu C, Tong D, Xiang S, Williams
K, Bai W, Li GM, Bepler G and Zhang X: Ubiquitin-specific peptidase
10 (USP10) deubiquitinates and stabilizes MutS Homolog 2 (MSH2) to
regulate cellular sensitivity to DNA damage. J Biol Chem.
291:10783–10791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao Y, Wei M, Li B, Liu Y, Lu Y, Tang Z,
Lu T, Yin Y, Qin Z and Xu Z: Functional role of eukaryotic
translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC.
Oncotarget. 7:24242–24251. 2016.PubMed/NCBI
|
|
15
|
Heinen CD: Translating mismatch repair
mechanism into cancer care. Curr Drug Targets. 15:53–64. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kamal NS, Soria JC, Mendiboure J,
Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand
P, Dunant A, et al: MutS homologue 2 and the long-term benefit of
adjuvant chemotherapy in lung cancer. Clin Cancer Res.
16:1206–1215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ko JC, Chiu HC, Syu JJ, Chen CY, Jian YT,
Huang YJ, Wo TY, Jian YJ, Chang PY, Wang TJ and Lin YW:
Down-regulation of MSH2 expression by Hsp90 inhibition enhances
cytotoxicity affected by tamoxifen in human lung cancer cells.
Biochem Biophys Res Commun. 456:506–512. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng Z, Zhou Z, Zhan N, Yuan J, Ye B, Gu
L, Wang J, Jian Z and Xiong X: USP10 expression in normal adrenal
gland and various adrenal tumors. Endocr Pathol. 26:302–308. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Politi K and Herbst RS: Lung cancer in the
era of precision medicine. Clin Cancer Res. 21:2213–2220. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang H and Shrager JB: CRISPR/Cas-mediated
genome editing to treat EGFR-mutant lung cancer: A personalized
molecular surgical therapy. EMBO Mol Med. 8:83–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCloskey P, Balduyck B, Van Schil PE,
Faivre-Finn C and O'Brien M: Radical treatment of non-small cell
lung cancer during the last 5 years. Eur J Cancer. 49:1555–1564.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Santarpia M, Rolfo C, Peters GJ, Leon LG
and Giovannetti E: On the pharmacogenetics of non-small cell lung
cancer treatment. Expert Opin Drug Metab Toxicol. 12:307–317. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing
T, Dong L, Tang E and Yang H: Over-expression of genes and proteins
of ubiquitin specific peptidases (USPs) and proteasome subunits
(PSs) in breast cancer tissue observed by the methods of RFDD-PCR
and proteomics. Breast Cancer Res Treat. 104:21–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grunda JM, Nabors LB, Palmer CA, Chhieng
DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE,
et al: Increased expression of thymidylate synthetase (TS),
ubiquitin specific protease 10 (USP10) and survivin is associated
with poor survival in glioblastoma multiforme (GBM). J Neurooncol.
80:261–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kitamura H, Kameda Y, Ito T and Hayashi H:
Atypical adenomatous hyperplasia of the lung. Implications for the
pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol.
111:610–622. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mori M, Kaji M, Tezuka F and Takahashi T:
Comparative ultrastructural study of atypical adenomatous
hyperplasia and adenocarcinoma of the human lung. Ultrastruct
Pathol. 22:459–466. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osanai M, Igarashi T and Yoshida Y: Unique
cellular features in atypical adenomatous hyperplasia of the lung:
Ultrastructural evidence of its cytodifferentiation. Ultrastruct
Pathol. 25:367–373. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beasley MB, Brambilla E and Travis WD: The
2004 World Health Organization classification of lung tumors. Semin
Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu
J and Gao FH: MicroRNA-191 promotes pancreatic cancer progression
by targeting USP10. Tumour Biol. 35:12157–12163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai B, Ma W, Bi C, Yang F, Zhang L, Han Z,
Huang Q, Ding F, Li Y, Yan G, et al: Long noncoding RNA H19
mediates melatonin inhibition of premature senescence of c-kit(+)
cardiac progenitor cells by promoting miR-675. J Pineal Res.
61:82–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guturi KK, Bohgaki M, Bohgaki T, Srikumar
T, Ng D, Kumareswaran R, El Ghamrasni S, Jeon J, Patel P, Eldin MS,
et al: RNF168 and USP10 regulate topoisomerase IIα function via
opposing effects on its ubiquitylation. Nat Commun. 7:126382016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li D, Zeng Z, Yu T, Qin J, Wu J, Song JC,
Zhou ZY and Yuan JP: Expression and clinical implication of S100A12
in gastric carcinoma. Tumour Biol. 37:6551–6559. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie KJ, He HE, Sun AJ, Liu XB, Sun LP and
Dong XJ: Expression of ERCC1, MSH2 and PARP1 in non-small cell lung
cancer and prognostic value in patients treated with platinum-based
chemotherapy. Asian Pac J Cancer Prev. 15:2591–2596. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Levallet G, Dubois F, Fouret P, Antoine M,
Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E,
Debieuvre D, et al: MSH2/BRCA1 expression as a DNA-repair signature
predicting survival in early-stage lung cancer patients from the
IFCT-0002 phase 3 trial. Oncotarget. 8:4313–4329. 2017. View Article : Google Scholar : PubMed/NCBI
|
